 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA PR...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA

Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 ENTR-601-44 clinical development program remains on track with data readout expected in second...

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in

 Latest Ratings for TRDA
 DateFirmActionFromTo Nov 2021Evercore ISI...

Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?

Entrada Therapeutics Inc. won't be able to start testing a Duchenne drug in the U.S. anytime soon, based on new feedback from the Food and Drug Administration...

Entrada shares slide as FDA maintains freeze on Duchenne drug

Entrada Therapeutics, Inc. (NASDAQ:TRDA  Get Free Report) CEO Dipal Doshi sold 1,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of...

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $16,230.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA  Free Report)  Investment analysts at William Blair issued their Q1 2025 earnings estimates for shares of Entrada Therapeutics in a report...

Q1 2025 Earnings Forecast for Entrada Therapeutics, Inc. (NASDAQ:TRDA) Issued By William Blair

Shareholders in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) may be thrilled to learn that the analysts have just...

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada's transition to a clinical-stage company Expanded the Company's...

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

Company transitions to clinical-stage with initiation of Phase 1 trial, cash runway expected through 2025Related Stocks: TRDA...

Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million

In trading on Monday, shares of Entrada Therapeutics Inc (TRDA) crossed above their 200 day moving average of 14.30, changing hands as high as 14.83 per share. Entrada Therapeutics Inc...

TRDA Makes Bullish Cross Above Critical Moving Average

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Watchers	91
52-Wk Low	$9.32
52-Wk High	$21.64

Market Cap	$455.47M
Volume (M)	74,313.00
52-Wk High	$21.64
52-Wk Low	$9.32

TRDA Entrada Therapeutics Inc

About

Feed

News

Earnings

Fundamentals